Case Report
Copyright ©The Author(s) 2017.
World J Clin Infect Dis. Nov 25, 2017; 7(4): 50-57
Published online Nov 25, 2017. doi: 10.5495/wjcid.v7.i4.50
Figure 1
Figure 1 Histologic findings. Histological section, H and E staining (scale bar × 10). Liver fragment with the presence of abundant inflammatory lymphoplasmacytic infiltrate with eosinophils and severe interface activity.
Figure 2
Figure 2 Histologic findings. Histological section H and E staining (scale bar x 40). Presence of lymphoplasmacytic infiltrate with eosinophils and hepatocytes with pericentral fibrosis inflammation.
Figure 3
Figure 3 Diagnostic algorithm suggested. Diagnostic algorithm suggested to differentiate between autoimmune hepatitis (AIH) of drug-induced liver injury (DILI). Following the suspension of the steroid, a long-term follow-up is recommended (6 mo to 3 year) so as not to lose a late relapse of autoimmune hepatitis. Adapted from EASL Clinical Practice Guidelines: Autoimmune hepatitis, 2015.
Figure 4
Figure 4 Transaminase values during follow-up. Aspartate transaminase (AST) and alanine transaminase (ALT) values (UI/L) and their relationship with the interventions carried out and date (DD/MM): At the start of the follow-up, the patient was already receiving antiretroviral therapy, in the first interventions there is some confusion that does not allow to differentiate whether the decrease in serum transaminase levels was due to the onset of immunosuppressive therapy or the interruption of the antiretroviral therapy; also there is no indication to show if the second peak elevation of transaminases was due to the resumption of the antiretroviral therapy or due to the decrease in the dose of immunosuppressive therapy. In the end, it may be noted that, although the antiretroviral therapy was reset, the decline of transaminases continued with the immunosuppressive therapy, which helped to confirm the diagnosis of autoimmune hepatitis. cART: Combination antiretroviral therapy.